Targeting Mitosis to Reprogram the Tumor Microenvironment: Combination Strategies for Cancer Immunotherapy

Dysregulated mitosis is a therapeutic vulnerability in cancer, but the consequences of mitotic targeting extend beyond tumor-cell death. Chromosome missegregation, micronucleus formation, and chromatin-bridge exposure can activate cytosolic DNA sensing and alter inflammatory signaling, immune recognition, and stromal interactions within the tumor microenvironment (TME). These responses are not uniformly antitumor. Acute mitotic perturbation may enhance innate immune activation and tumor-cell susceptibility to immune elimination, whereas persistent chromosomal instability can promote inflammatory adaptation, myeloid immunosuppression, and immune escape. This distinction has important implications for combining antimitotic agents with immunotherapy. Here, we examine the molecular mechanisms linking mitotic disruption to TME remodeling, with particular emphasis on signaling through cyclic GMP–AMP synthase (cGAS) and stimulator of interferon genes (STING), immune checkpoint regulation, myeloid-cell responses, and stromal reorganization. We evaluate combination strategies involving immune checkpoint blockade, innate immune modulation, myeloid targeting, radiotherapy, and cell-death-enhancing interventions. Although preclinical studies provide mechanistic support for several approaches, clinical evidence remains uneven, and the immune consequences of individual antimitotic agents are difficult to predict across tumor types. We propose a testable framework integrating baseline chromosomal instability, p53 status, innate immune competence, and early treatment-induced biomarkers to guide therapeutic selection and scheduling. Translating this framework into clinical practice will require prospective validation, clearer separation of drug-specific effects from general mitotic stress responses, and evidence that immune remodeling improves patient outcomes.

Authors

Publication Details

Journal
Cancer Biome and Targeted Therapy
Published
2026-11-14
DOI
https://doi.org/10.66505/cbtt.v1i4.62
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting Mitosis to Reprogram the Tumor Microenvironment: Combination Strategies for Cancer Immunotherapy

Fazhi Yu, Zhenye Yang, Jing Guo, Shuaishuai Ji
Cancer Biome and Targeted Therapy
Cancer Immunotherapy and Biomarkers
article

Targeting Mitosis to Reprogram the Tumor Microenvironment: Combination Strategies for Cancer Immunotherapy

Fazhi Yu, Zhenye Yang, Jing Guo, Shuaishuai Ji
article en

Abstract

Dysregulated mitosis is a therapeutic vulnerability in cancer, but the consequences of mitotic targeting extend beyond tumor-cell death. Chromosome missegregation, micronucleus formation, and chromatin-bridge exposure can activate cytosolic DNA sensing and alter inflammatory signaling, immune recognition, and stromal interactions within the tumor microenvironment (TME). These responses are not uniformly antitumor. Acute mitotic perturbation may enhance innate immune activation and tumor-cell susceptibility to immune elimination, whereas persistent chromosomal instability can promote inflammatory adaptation, myeloid immunosuppression, and immune escape. This distinction has important implications for combining antimitotic agents with immunotherapy. Here, we examine the molecular mechanisms linking mitotic disruption to TME remodeling, with particular emphasis on signaling through cyclic GMP–AMP synthase (cGAS) and stimulator of interferon genes (STING), immune checkpoint regulation, myeloid-cell responses, and stromal reorganization. We evaluate combination strategies involving immune checkpoint blockade, innate immune modulation, myeloid targeting, radiotherapy, and cell-death-enhancing interventions. Although preclinical studies provide mechanistic support for several approaches, clinical evidence remains uneven, and the immune consequences of individual antimitotic agents are difficult to predict across tumor types. We propose a testable framework integrating baseline chromosomal instability, p53 status, innate immune competence, and early treatment-induced biomarkers to guide therapeutic selection and scheduling. Translating this framework into clinical practice will require prospective validation, clearer separation of drug-specific effects from general mitotic stress responses, and evidence that immune remodeling improves patient outcomes.

Cancer Biome and Targeted Therapy
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon